Chlorproethazine hydrochloride is an orally active phenothiazine compound. Chlorproethazine hydrochloride can eliminate spasticity when administered intravenously and also effectively reduce rigidity in decerebrate cats. Chlorproethazine hydrochloride can be used in the research of neurological diseases.

Chlorohexane-PEG-clozapine is a HaloTag PROTAC degrader based on Clozapine. Chlorohexane-PEG-clozapine leads to a significant decrease in the luminescence intensity and protein level of Halo-Eluc. (Pink: Ligands for Target Protein for PROTAC Target protein ligand; Blue: Ligands for E3 Ligase ligand ; Black: linker).

Chitin, from crab carapace is a long-chain polymer of N-acetylglucosamine with β-(1-4) linkages. Chitin, from crab carapace is found in the exoskeleton of crabs. Chitin, from crab carapace inhibits the activation of NF-κB p65, alters the translocation of NF-κB p65 to the nucleus, and interacts with the cell wall of Candida species. Chitin, from crab carapace exerts antifungal and anti-inflammatory effects. Chitin, from crab carapace can be used in the research of gastric ulcer and candidiasis.

CHIR-29498 is an antibacterial peptoid. CHIR-29498 is active against both Gram-positive and Gram-negative bacteria. CHIR-29498 can be used for the study of fatal Staphylococcus aureus.

CHIKV-IN-1 (Compound 3a) is a compound that inhibits the Chikungunya virus (CHIKV) with an EC50 of 0.12 μM. CHIKV-IN-1 is a potent inhibitor of the S-adenosyl-L-homocysteine hydrolase (SAH hydrolase), with an IC50 of 0.36 μM. CHIKV-IN-1 is only effective against CHIKV and some other alphaviruses, but has no activity against other RNA viruses such as SARS-CoV, MERS-CoV, and ZIKV. CHIKV-IN-1 has extremely low cytotoxicity (CC₅₀ > 250 μM), and it has an extremely high selectivity index (SI > 2083). CHIKV-IN-1 can be used in research on anti-Chikungunya virus.

CHI3L1-IN-7 is a selective CHI3L1 inhibitor with a Kd of 7.40 μM and an IC50 of 15.4 μM. CHI3L1-IN-7 blocks CHI3L1's interaction with galectin-3, inhibits STAT3 phosphorylation, reduces the viability of multicellular 3D glioblastoma spheroids. CHI3L1-IN-7 can be used for the research of glioblastoma and CHI3L1-mediated tumor immune regulation.

CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor with a Kd of 19.11 μM for hCHI3L1. CHI3L1-IN-6 blocks CHI3L1-Galectin-3 interaction. CHI3L1-IN-6 reduces STAT3 signaling. CHI3L1-IN-6 exhibits anti-cancer activity against glioblastoma.

CHF-6333 xinafoate is a neutrophil elastase (NE) inhibitor (IC50 = 0.21 nM; KD = 0.16 nM). CHF6333 xinafoate retains its activity in both human (IC50 = 0.22 nM) and rat (IC50 = 3.63 nM) proteases. CHF6333 xinafoate exhibits inhibitory activity against Proteinase 3 (IC50 = 22 nM). CHF-6333 xinafoate can be used for the study of bronchiectasis (BE).

Chenodeoxycholyl-putrescine is a polyamine bile amidate.

Chaperone complex ligand 1 is a chaperone ligand for HSP90. Chaperone complex ligand 1 can be connected to the MET ligand by a linker to synthesis of MET degrader OZD-MET 01.

CGS 27023A free base is a non-peptidic and orally active MMP inhibitor with the Ki values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A free base prevents cartilage degradation in stromelysin-induced rabbit cartilage degradation model. CGS 27023A free base can be used for study of arthritis.

CGS 24012 (DPMA) is a selective adenosine A2 agonist. CGS 24012 produces significant increases in cardiac output. CGS 24012 reduces renal vascular resistance to the greatest extent and produces a concomitant significant increase in renal blood flow. CGS 24012 can be used in the research of hypertension.

CGP-45688 is an orally active non-steroidal aromatase inhibitor with an ED50 of 30-100 μg/kg. CGP-45688 can reduce the level of estrogen in the body, thereby inhibiting the growth of estrogen-dependent tumors. CGP-45688 inhibits the growth of estrogen-dependent breast tumors in rat models. CGP-45688 disrupts the ovarian cycle and inhibits the weight of the uterus. CGP-45688 can be used for the study of breast cancer.

CGP 47645 is a long-acting nonsteroidal aromatase inhibitor. CGP 47645 can significantly affect testicular function. CGP 47645 can be used to study the physiological role of estrogen in regulating testicular function.

CGP 29030A is an orally effective and specific analgesic agent. CGP 29030A inhibits nociceptive spinal cord neurons without affecting normal sensory functions. CGP 29030A also inhibits gamma motor neurons, which may be beneficial for studying pain disorders that occur concurrently due to increased motor activity (such as cramp, spasm).

cGAS-IN-9 is a cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) inhibitor, with IC50 values of 27.5 nM and 5.15 μM against human and murine cGAS, respectively. cGAS-IN-9 shows weak inhibitory activity against human soluble adenylate cyclase, with an IC50 of 26.4 μM. cGAS-IN-9 inhibits dsDNA-induced expression of IFNB1 and CXCL10, as well as activation of the NF-κB pathway, in human immune cells. cGAS-IN-9 can be used in research related to cGAS-dependent inflammatory diseases.

cGAS-IN-6 (14) is a cGAS inhibitor. cGAS-IN-6’s core structure is a fused imidazole ring system. cGAS-IN-6 can be used for research on autoimmune conditions.

CG-1521 is a histone deacetylase (HDAC) inhibitor that stabilizes Ac-Lys373 P53, increases P21 levels and HDAC2 degradation. CG-1521 can inhibit proliferation, induce cell cycle arrest and apoptosis. CG-1521 promotes Bax translocation to the mitochondria and cleavage. CG-1521 downregulates KIF4, Aurora B and Nek2 protein expression and DNA synthesis. CG-1521 can be used for the research of prostate cancer and inflammatory breast cancer.

Cevipabulin (TTI-237) fumarate dihydrate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [3H]NSC 49842 to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line.

Cenpemlin is a CENP-M inhibitor that disrupts the CENP-M/CENP-L interaction. Cenpemlin can be used for investigating centromere-kinetochore interactions and dynamic kinetochore assembly during cell division.

Cefpodoxime (Cefpodoxime acid) sodium is a potent antibiotic active against gram-positive and gram-negative bacteria. Cefpodoxime inhibits the majority of cells in microbial populations. Cefpodoxime sodium can be used for acute otitis media, sinusitis and tosillopharyngitis research.

Ceftezole (GR69153) is a broad-spectrum cephalosporin antibiotic and an α-glucosidase inhibitor. Ceftezole inhibits bacterial cell lysis by inhibiting cell wall synthesis and binding to penicillin-binding proteins (PBPs). Ceftezole exhibits in vivo anti-diabetic activity in diabetic mice. Ceftezole can be used in antibacterial and anti-diabetic research.

CE-1037 (MDL 201,404YA) is a selective inhibitor of human neutrophil elastase (HNE) (Ki: 0.45 nM). CE-1037 prevents the pulmonary hemorrhage induced by intratracheal instillation of HNE. CE-1037 can be used for research of pulmonary diseases, such as COPD.

CDK9-IN-49 is a CDK9 inhibitor with an IC50 of 7.32 nM. CDK9-IN-49 inhibits the proliferation of various cancer cells. CDK9-IN-49 can be used in the research of cancers such as acute myeloid leukemia and prostate cancer.

CDK9-IN-48 is a CDK9 inhibitor with an IC50 of 1.37 nM. CDK9-IN-48 inhibits the proliferation of various cancer cells. CDK9-IN-48 can be used in the research of cancers such as acute myeloid leukemia and prostate cancer.

CDK9-IN-46 (Compound Formula I) is a CDK9 inhibitor. CDK9-IN-46 can be used for the research of cancer.

CDK8-IN-2 is an orally active CDK8 inhibitor of an IC50 values of 0.010 μM. CDK8-IN-2 shows a CDK19 IC50 value of 0.026 μM. CDK8-IN-2 inhibits phospho-STAT1, a pharmacodynamic biomarker of CDK8. CDK8-IN-2 inhibits WNT pathway activity. CDK8-IN-2 can be used for the research of colorectal carcinoma.

CDK7-IN-33 (formula Ⅰ) is a pyrimidine derivative and also a CDK7 kinase inhibitor. CDK7-IN-33 is applicable to the research of cancer, inflammation, cardiovascular diseases, infectious diseases, immune diseases and metabolic diseases.

SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor that disrupts the SHOC2-RAS protein-protein interaction. It exhibits an IC50 of 0.048 μM and a KD of 0.065 μM against NRASQ61R. The compound inhibits the SMP phosphatase complex, resulting in elevated CRAFS259 phosphorylation and subsequent blockade of the MAPK signaling pathway (evidenced by reduced pMEK and pERK levels). This inhibition induces tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 serves as a research tool for investigating NRASQ61R-mutant malignancies including melanoma and colorectal cancer.

CDK4-IN-4 (example 30) is a selective CDK4 inhibitor (IC50＜10 nM) that can be used in cancer research.